Compare COCO & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COCO | HTFL |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2021 | 2025 |
| Metric | COCO | HTFL |
|---|---|---|
| Price | $54.19 | $26.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $55.13 | $39.50 |
| AVG Volume (30 Days) | ★ 942.7K | 671.4K |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.16 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $609,286,000.00 | $161,881,000.00 |
| Revenue This Year | $18.22 | $40.42 |
| Revenue Next Year | $13.69 | $22.27 |
| P/E Ratio | $46.98 | ★ N/A |
| Revenue Growth | 23.12 | ★ 85.70 |
| 52 Week Low | $25.79 | $25.75 |
| 52 Week High | $55.09 | $41.22 |
| Indicator | COCO | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 70.62 | N/A |
| Support Level | $53.31 | N/A |
| Resistance Level | $55.03 | N/A |
| Average True Range (ATR) | 1.78 | 0.00 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 91.51 | 0.00 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.